Transcoronary gradient of plasma microRNA 423-5p in heart failure: Evidence of altered myocardial expression

Biomarkers

Volumn 19, Issue 2, 2014, Pages 135-141

  Goldraich, Livia A ^a,b   Martinelli, Nidiane C ^a,b   Matte, Ursula ^b   Cohen, Carolina ^a,b   Andrades, Michael ^a,b   Pimentel, Maurício ^a,b   Biolo, Andréia ^a,b   Clausell, Nadine ^a,b   Rohde, Luis E ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Coronary sinus; Left ventricular dysfunction; MicroRNA

Indexed keywords

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; HEART FAILURE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; PILOT PROJECTS;

EID: 84894543240     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2013.870605     Document Type: Article

References (27)

1. Bauters C, Kumarswamy R, Holzmann A, et al. (2013). Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction. Int J Cardiol 168:1837-40.
2. Castoldi G, Di Gioia CR, Bombardi C, et al. (2012). MiR-133a regulates collagen 1A1: potential role of miR-133a in myocardial fibrosis in angiotensin II-dependent hypertension. J Cell Physiol 227:850-6.
3. D'Alessandra Y, Devanna P, Limana F, et al. (2010). Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 31:2765-73.
4. De Rosa S, Fichtlscherer S, Lehmann R, et al. (2011). Transcoronary concentration gradients of circulating microRNAs. Circulation 124: 1936-44.
5. Dickinson BA, Semus HM, Montgomery RL, et al. (2013). Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure. Eur J Heart Fail 15: 650-9.
6. Divakaran V, Mann DL. (2008). The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res 103:1072-83.
7. Dorn 2nd GW. (2010). Therapeutic potential of microRNAs in heart failure. Curr Cardiol Rep 12:209-15.
8. Fan KL, Zhang HF, Shen J, et al. (2013). Circulating microRNAs levels in Chinese heart failure patients caused by dilated cardiomyopathy. Indian Heart J 65:12-16.
9. Fukushima Y, Nakanishi M, Nonogi H, et al. (2011). Assessment of plasma miRNAs in congestive heart failure. Circ J 75:336-40.
10. Gallo A, Tandon M, Alevizos I, Illei GG. (2012). The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One 7:e30679.
11. Goren Y, Kushnir M, Zafrir B, et al. (2012). Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail 14:147-54.
12. Kroh EM, Parkin RK, Mitchell PS, Tewari M. (2010). Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 50: 298-301.
13. Levey AS, Bosch JP, Lewis JB, et al. (1999). A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461-70.
14. Maeder MT, Mariani JA, Kaye DM. (2010). Hemodynamic determinants of myocardial B-type natriuretic peptide release: relative contributions of systolic and diastolic wall stress. Hypertension 56:682-9.
15. Margulies KB, Bednarik DP, Dries DL. (2009). Genomics, transcriptional profiling, and heart failure. J Am Coll Cardiol 53:1752-9.
16. Matkovich SJ, van Booven DJ, Youker KA, et al. (2009). Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation 119:1263-71.
17. Olivieri F, Rippo MR, Procopio AD, Fazioli F. (2013). Circulating inflamma-miRs in aging and age-related diseases. Front Genet 4:121.
18. Rai AJ, Gelfand CA, Haywood BC, et al. (2005). HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 5:3262-77.
19. Recchioni R, Marcheselli F, Olivieri F, et al. (2013). Conventional and novel diagnostic biomarkers of acute myocardial infarction: a promising role for circulating microRNAs. Biomarkers 18: 547-58.
20. Satoh M, Minami Y, Takahashi Y, et al. (2010). Expression of microRNA-208 is associated with adverse clinical outcomes in human dilated cardiomyopathy. J Card Fail 16:404-10.
21. Thum T, Catalucci D, Bauersachs J. (2008). MicroRNAs: novel regulators in cardiac development and disease. Cardiovasc Res 79: 562-70.
22. Tijsen AJ, Creemers EE, Moerland PD, et al. (2010). MiR423-5p as a circulating biomarker for heart failure. Circ Res 106:1035-9.
23. van Rooij E, Sutherland LB, Liu N, et al. (2006). A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 103:18255-60.
24. van Rooij E, Sutherland LB, Thatcher JE, et al. (2008). Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 105: 13027-32.
25. Wang GK, Zhu JQ, Zhang JT, et al. (2010). Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31:659-66.
26. Widera C, Gupta SK, Lorenzen JM, et al. (2011). Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol 51:872-5.
27. Zile MR, Mehurg SM, Arroyo JE, et al. (2011). Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients after myocardial infarction. Circ Cardiovasc Genet 4: 614-19.